[go: up one dir, main page]

MX2016004660A - Composiciones de peptido novedosas. - Google Patents

Composiciones de peptido novedosas.

Info

Publication number
MX2016004660A
MX2016004660A MX2016004660A MX2016004660A MX2016004660A MX 2016004660 A MX2016004660 A MX 2016004660A MX 2016004660 A MX2016004660 A MX 2016004660A MX 2016004660 A MX2016004660 A MX 2016004660A MX 2016004660 A MX2016004660 A MX 2016004660A
Authority
MX
Mexico
Prior art keywords
compositions
peptides
amino acids
formula
novel peptide
Prior art date
Application number
MX2016004660A
Other languages
English (en)
Inventor
Franklin Richard
Original Assignee
Tarix Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tarix Pharmaceuticals Ltd filed Critical Tarix Pharmaceuticals Ltd
Publication of MX2016004660A publication Critical patent/MX2016004660A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona, entre otras cosas, péptidos y composiciones novedosas para tratar una enfermedad.
MX2016004660A 2013-10-11 2014-10-01 Composiciones de peptido novedosas. MX2016004660A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361890056P 2013-10-11 2013-10-11
US201461940095P 2014-02-14 2014-02-14
PCT/US2014/058646 WO2015054006A2 (en) 2013-10-11 2014-10-01 Novel peptide compositions

Publications (1)

Publication Number Publication Date
MX2016004660A true MX2016004660A (es) 2016-11-14

Family

ID=52813728

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016004660A MX2016004660A (es) 2013-10-11 2014-10-01 Composiciones de peptido novedosas.

Country Status (13)

Country Link
EP (1) EP3054967A4 (es)
JP (1) JP2017501967A (es)
KR (1) KR20160065969A (es)
CN (1) CN105828831A (es)
AU (1) AU2014332346B2 (es)
BR (1) BR112016007816A2 (es)
CA (1) CA2926641A1 (es)
CL (1) CL2016000836A1 (es)
IL (1) IL244956B (es)
MX (1) MX2016004660A (es)
RU (1) RU2016112931A (es)
SG (1) SG11201602661PA (es)
WO (1) WO2015054006A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017150327A1 (ja) * 2016-03-03 2017-09-08 不二製油グループ本社株式会社 神経栄養因子の脳内分泌促進するための食品添加用組成物
JP6983247B2 (ja) * 2017-02-16 2021-12-17 ケアジェン カンパニー, リミテッドCaregen Co., Ltd. サリチル酸とペプチドとの結合体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4244946A (en) 1979-06-11 1981-01-13 The Salk Institute For Biological Studies Water-soluble peptides affecting gonadal function
US4305872A (en) 1979-10-19 1981-12-15 Kenneth Wingrove Polypeptide derivatives
US4316891A (en) 1980-06-14 1982-02-23 The Salk Institute For Biological Studies Extended N-terminal somatostatin
WO1998002452A2 (en) 1996-07-12 1998-01-22 Mcgill University Compounds and methods for modulating cell adhesion
AU2001231154A1 (en) 2000-01-24 2001-07-31 Adherex Technologies Inc. Peptidomimetic modulators of cell adhesion
US7563862B2 (en) 2001-08-24 2009-07-21 Neuren Pharmaceuticals Limited Neural regeneration peptides and methods for their use in treatment of brain damage
EP1572887A4 (en) * 2001-08-24 2008-12-24 Neuren Pharmaceuticals Ltd NERVE REGENERATING PEPTIDE AND METHOD FOR THEIR USE IN THE TREATMENT OF A BRAIN DAMAGE
AU2003293807A1 (en) * 2002-12-24 2004-07-22 Algonomics N.V. Mhc class i restricted t-cell stimulating peptides from hepatitis b virus
JP5026083B2 (ja) * 2003-10-31 2012-09-12 クロンズ ホールディングズ カンパニー リミテッド 神経再生ペプチド及び脳損傷治療におけるそれらの使用方法
WO2007011595A2 (en) 2005-07-15 2007-01-25 Neuren Pharmaceuticals Limited Neural regeneration peptides and antioxidants protect neurons from degeneration
CA2804618C (en) * 2010-07-09 2020-09-08 Dana-Faber Cancer Institute, Inc. Stabilized insulinotropic peptides and methods of use
WO2013119870A1 (en) * 2012-02-10 2013-08-15 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of peripheral vascular disease

Also Published As

Publication number Publication date
CA2926641A1 (en) 2015-04-16
EP3054967A2 (en) 2016-08-17
RU2016112931A (ru) 2017-11-16
SG11201602661PA (en) 2016-05-30
JP2017501967A (ja) 2017-01-19
IL244956A0 (en) 2016-05-31
AU2014332346B2 (en) 2019-01-24
CN105828831A (zh) 2016-08-03
EP3054967A4 (en) 2017-04-19
WO2015054006A2 (en) 2015-04-16
BR112016007816A2 (pt) 2017-12-05
KR20160065969A (ko) 2016-06-09
AU2014332346A1 (en) 2016-05-05
IL244956B (en) 2019-10-31
WO2015054006A3 (en) 2015-06-04
RU2016112931A3 (es) 2018-06-20
CL2016000836A1 (es) 2016-09-16

Similar Documents

Publication Publication Date Title
PH12014501924A1 (en) Xten conjugate compositions and methods of making same
PH12017500866A1 (en) Targeted xten conjugate compositions and methods of making same
MX369818B (es) Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
MX2019000566A (es) Suministro mediado por ve de conjugados de proteína de enlace-molécula pequeña.
MY187047A (en) Selective pyy compounds and uses thereof
MY161773A (en) Amylin analogues and pharmaceutical compositions thereof
IN2013MU03583A (es)
BR112012029975A2 (pt) peptídeo como medicamento, em particular para o tratamento do câncer.
MX362432B (es) Variantes de oxm pegilada.
MX348823B (es) Formulaciones estables de linaclotida.
IN2014DN00101A (es)
MX2018014023A (es) Compuestos de citocina inhibidora de macrofagos 1 (mic-1) y uso de estos.
EP4414376A3 (en) Novel depsipeptide and uses thereof
EA201591752A1 (ru) Дипептидные и трипептидные эпоксикетонные ингибиторы протеазы
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
PH12019550241A1 (en) Mic-1 compounds and uses thereof
CY1119036T1 (el) Νεοι αγωνιστες του υποδοχεα τυπου 2 της αγγειοτενσινης (ατ2) και χρησεις τους
MX2020012989A (es) Agente terapeutico para la fibrosis.
MX2013012187A (es) Formulaciones topicas de tipo suspension que comprenden depsipeptido ciclico.
EA201991023A1 (ru) Фармацевтическая композиция для парентерального введения, содержащая карглумовую кислоту
WO2015024022A3 (en) Designed peptides for tight junction barrier modulation
MX2015002279A (es) Peptido pntx(19) sintético, composición farmacéutica.y uso.
NZ732301A (en) Peptide compound, preparation method therefor, and application thereof
MX2016004660A (es) Composiciones de peptido novedosas.
MX377823B (es) Composición nasal con capacidades de formación de película.